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Recently the sequencing of the human genome has become a major biological and clinical research field.
However, the public health impact of this new technology with focus on the financial effect is not yet to be
foreseen. To provide an overview of the current health economic evidence for genome sequencing, we conducted
a thorough systematic review of the literature from 17 databases. In addition, we conducted a hand search. Starting
with 5 520 records we ultimately included five full-text publications and one internet source, all focused on cost
calculations. The results were very heterogeneous and, therefore, difficult to compare. Furthermore, because the
methodology of the publications was quite poor, the reliability and validity of the results were questionable. The
real costs for the whole sequencing workflow, including data management and analysis, remain unknown. Overall,
our review indicates that the current health economic evidence for genome sequencing is quite poor. Therefore,
we listed aspects that needed to be considered when conducting health economic analyses of genome
sequencing. Thereby, specifics regarding the overall aim, technology, population, indication, comparator, alternatives
after sequencing, outcomes, probabilities, and costs with respect to genome sequencing are discussed. For further
research, at the outset, a comprehensive cost calculation of genome sequencing is needed, because all further
health economic studies rely on valid cost data. The results will serve as an input parameter for budget-impact
analyses or cost-effectiveness analyses.
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Since the publication of a draft sequence of the human
genome in 2001 [1,2] and the completion of a full
sequence through the Human Genome Project in 2003
[3], the sequencing of the human genome has become a
major biological and clinical research field. These research
activities aim to thoroughly understand genetic diseases, e.
g. cancer or rare diseases, and correspondingly to develop
targeted medicines that prevent or cure these illnesses.
The literature distinguishes between several types of
genome sequencing based on the extent of the analysis.
The sequencing of every single base in the human
genome, whole-genome sequencing (WGS), is the most
comprehensive type.
Whole-exome sequencing (WES) focuses on the pro-
tein-coding portion of the genome. The exome represents* Correspondence: mf@ivbl.uni-hannover.de
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2013only about 1% of the full genome, or approximately 30
megabases (Mb) [4]. The entire human genome consists
of three billion bases. Finally single genes or specific subsets
of genes can be explored. In general, the advantage of
targeted sequencing approaches is the increased sequence
coverage of regions of interest and a higher throughput in
comparison with comprehensive sequencing methods [5,6].
Several sequencing technologies have been developed
throughout the years. Since the introduction of the
Sanger method [7] (first-generation sequencing) in the
1970s, these technologies have undergone various modi-
fications. The major aims of the development of new
technologies (next-generation sequencing), with regard
to WGS, were to reduce the time and costs for sequen-
cing. The Illumina HiSeq is currently, beside other
sequencing platforms, widely-used for WGS.
The rapid development of these technologies and the
increasing number of publications show that many
scientists are involved in this research field. Competition
is promoted by scientific vision and by scientific prizesOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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often cited ‘race to the $1 000 genome’ [8,9] has played
an important role. The origin of this figure lies in the
vision offered by Collins et al. on behalf of the Human
Genome Research Institute, formulated in 2003 [3]. The
authors want to ‘provoke creative dreaming’. One vision
is the ‘ability to sequence deoxyribonucleic acid (DNA)
at costs that are lower by four to five orders of magni-
tude than the current cost, allowing a human genome to
be sequenced for $1 000 or less’. In addition to the race
to the $1 000 genome, the X Prize Foundation in the US
wants to grant $10 million to the first team, being able
to design a rapid, accurate, and economic system. The
technology must be capable of sequencing 100 human
genomes in ten days. Furthermore, the error rate needs
to be <1 in 100 000 bases, the coverage at least 98%, and
the cost no more than $10 000 for each sequenced
genome [10]. However, the competition was cancelled
in 2013.
The costs or, in, general the economic effect of these
new technologies are of special interest especially from a
public health point of view. Since there are on-going
discussions on the application of these technologies to
every new-born, to all newly diagnosed cancer patients
or to even the broad population, it is necessary to focus
on health economic aspects first in order to gain insight
into the potential public health impact.
In this review, we analyse the current health economic
evidence with respect to the sequencing of the human
genome. Health economists distinguish between several
methodological approaches. On one hand, some studies
calculate the costs of new technologies and their eco-
nomic burden. On the other hand, full economic evalua-
tions go beyond pure effectiveness or cost measurements
by combining assessments of costs and the consequences/
outcomes of defined diagnostic procedures or interven-
tions. Thereby, three evaluation approaches can be distin-
guished: cost-effectiveness analysis, cost-utility analysis,
and cost-benefit analysis [11]. Cost-effectiveness analyses
evaluate alternative technologies (e.g. genome sequencing
versus standard diagnostic techniques) in comparing costs
and a common effectiveness parameter (e.g. life-years
gained through the diagnostic link of patient subgroups to
specific treatments). Cost-utility analyses use utilities like
quality-adjusted life-years (QALYs) as benefit parameters.
The two main advantages of cost-utility analysis are that
they adjust for quality of life and allow comparisons
between indications. In cost-benefit analyses, not only the
cost but also the benefit is measured in monetary units.
However, because of the difficulty in expressing patient
benefit in monetary terms, this approach is rarely used in
practice. The incremental approach is a common factor in
all economic evaluations: they divide the additional costs
of alternative A versus alternative B by the additionalbenefit of alternative A versus alternative B, resulting in
the incremental cost-effectiveness ratio (ICER). It states
the costs per additional benefit parameter (e.g. QALYs),
which need to be afforded in the case of implementing
alternative A in routine care.
In the context of genome sequencing, the following
health economic questions are of interest. How much do
the sequencing technologies cost? Do health economic
studies, which estimate the potential benefit of genome
sequencing in relation to its costs, exist? What is the es-
timated health economic burden of these technologies?
Therefore, the aim of this study was to conduct a sys-
tematic literature review of the current health economic
evidence for genome sequencing. We focus not only on
WGS, but also on other sequencing strategies like WES,
in order to obtain a thorough overview of the current
health economic evidence with respect to sequencing.
Finally, based on the findings of the literature and the
general knowledge on health economics, e.g. [11], we
emphasize aspects that are important for health eco-
nomic studies in this particular field of research.
Materials and methods
A systematic literature search was conducted via
database research of the German Institute for Medical
Documentation and Information (DIMDI). DIMDI
develops and operates database-supported information
systems for drugs and medical devices. Hence, database
research via DIMDI represents a standard for conducting
international systematic literature reviews in Germany.
The following 17 German and international data-
bases were searched: Deutsches Ärzteblatt, BIOSIS
Previews, Cochrane Database of Systematic Reviews,
DAHTA-Datenbank, EMBASE Alert, EMBASE, GMS,
GMS Meetings, Social SciSearch, Health Technology
Assessment Database, SciSearch, Krause & Pachernegg
Verlagsdatenbank, MEDLINE, NHS Economic Evalu-
ation Database, Thieme Verlagsdatenbank, and Thieme
Verlagsdatenbank PrePrint.
The full-text search included publications published in
German or in English from 2002 to 2012. An update
was performed May 2013 in MEDLINE which listed the
majority of all hits.
We used the following combination of German and
English search terms, with * serving as a wildcard:
1 Title: (sequenc* OR *sequenz*)
AND
2 Text fields: (cost* OR economic* OR quality of life*
OR QALY OR quality adjusted life years OR kosten*
OR *ökonomi* OR lebensqualität)
Full-text publications written in English or in German
were included. After the elimination of duplicates, two
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remaining publications independently and identified
possible relevant articles with health economic content.
We focused on identifying cost analyses or studies that
estimate the potential benefit of genome sequencing in
relation to its costs (e.g. cost-effectiveness studies). The
two researchers’ results were combined and disparities
were discussed. After ordering the publication, we went
through the full texts thoroughly.
Results
The database search identified 5 520 records, of which 3
271 were duplicates. After screening the titles and/or
abstracts, 2 180 publications were excluded and 69 full-
text articles were assessed for eligibility. The inclusion
criteria were fulfilled by five articles, which were used
for this review. In addition, we included one publication
from an online source. Even though it is not a full-print
publication it is often cited in this context. Therefore, it
was included. Figure 1 summarizes the search process.
The other full-text publications were not included
because they did not contain comprehensive cost or
cost-effectiveness data. Studies based on identical data
were excluded from this review.
First, we focused on the five full-text publications. All
five studies (see Table 1) compared cost data for the use
of different sequencing platforms. No publication giving
results of a cost-effectiveness analysis or a comparable
study was found.Figure 1 Flow diagram of articles identified and evaluated on the basOne major distinction between the reviewed studies is
the consideration of acquisition costs. Tucker et al. [12]
state that commercially available instruments cost
between $400 000 and $1 350 000 each, not including
costs associated with the software, training, and data
transfer as well as storage. However, Glenn [13] states
that the costs for the second-generation platforms
currently range from $ 49 500 to $ 695 000. Moreover,
the cost calculation process differs between the in-
cluded studies. The cost calculation process was not
described in a transparent way in any of the reviewed
studies.
Costs per Mb for the application of the sequencing
platforms differ. Moreover, the cost per Mb for the use
of identical sequencing technologies varies between the
identified studies, because they might include different
factors like depreciation costs, personal costs, or lab
facility costs. Using the example of the Roche/454 GS
FLX Titanium, Glenn determined the cost per Mb of
$12.40. In contrast, Pareek et al. [14] calculated a cost
per Mb of $84.39. The Sanger method is the most
expensive sequencing technology, costing approximately
$500 per Mb [18]. The human genome consists of
approximately 3 000 Mb. Hence, the WGS process
would cost approximately $1 500 000. However, genome
sequencing with the Illumina HiSeq 2000 platform
seems to be one of the least expensive alternatives, cost-
ing $0.10 per Mb [13]. In this case, only $300 are
required for the WGS process. Technical specifications
differ between the sequencing platforms. Especially rawis of the inclusion criteria.
Table 1 Included studies
Author Title Bibliography
Glenn TC Field guide to next-generation DNA sequencers Mol Ecol Resour 2011; 11: 759-769
Kircher M, Kelso J High-throughput DNA sequencing—concepts and limitations Bioessays 2010; 32: 524-536
Pareek CS, Smoczynski R, Tretyn A Sequencing technologies and genome sequencing J Appl Genetics 2011; 52: 413-435
Shendure J, Ji H Next-generation DNA sequencing Nat Biotechnol 2008; 26: 1135-1145
Tucker T, Marra M, Friedman JM Massively Parallel Sequencing: The Next Big Thing in Genetic Medicine Am J Hum Genet 2009; 85: 142-154
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over, a high throughput per day is necessary for WGS.
In Table 2, we merged the results of the included
studies.
Finally, the internet source, that we have already
mentioned, was evaluated. The National Human
Genome Research Institutes webpage informs about
longitudinal sequencing costs and updates the data on a
regular basis [15]. Two cost categories are distinguished
and defined as production and non-production costs.
The cost for sequencing decreases faster than Moore’s
law [16], which was $0.06 per Mb and $5 826 per gen-
ome in April 2013. However, the cost calculation processTable 2 Results of the reviewed studies
Author (publication year) Throughpu
Sanger Kircher et al. (2010) 6
Roche/454 GS FLX Titanium Shendure et al. (2008) -
Tucker et al. (2009) 1 200
Kircher et al. (2010) 750
Glenn (2011) -
Pareek et al. (2011) 1 000
Illumina Genome Analyzer II/IIx Tucker et al. (2009) 2 500
Kircher et al. (2010) 5 000
Illumina Solexa Shendure et al. (2008) -
Pareek et al. (2011) 1 500
Illumina HiSeq 2000 Glenn (2011) -
Applied Biosystems SOLiD 4 Shendure et al. (2008) -
Pareek et al. (2011) 1 850
Tucker et al. (2009) 2 500
Kircher et al. (2010) 5 000
Life Technologies SOLiD 5500 Glenn (2011) -
Life Technologies SOLiD 5500xl Glenn (2011) -
Helicos HeliScope Shendure et al. (2008) -
Tucker et al. (2009) 3 100
Kircher et al. (2010) 5 000
Glenn (2011) -
Pareek et al. (2011) 2 500
Polonator Shendure et al. (2008) -is not stated, and no cost values are given for the sepa-
rated categories.
The results varied between assessment dates due to the
decreasing costs of sequencing technologies. Technical
adjustments to the sequencing platforms, such as cover-
age, differ between the included studies as well. Although
some authors have gathered cost data on the existing
sequencing platforms, the real costs for the whole sequen-
cing workflow remain a ‘black box’. And the reason for
this is, that the numerous resources connected to genome
sequencing are insufficiently incorporated into the cost
calculations. To conduct an adequate cost analysis, all
necessary resources required for the application of WGSt Mb/day Bases/read Raw
accuracy
Cost per
instrument
Cost per Mb
approximately
800 0.99991 - $500.00
250 - $500 000 $60.00
400 0.99 - $84.40
400 0.9991 - $20.00
400 0.99 - $12.40
400 0.995 $500 000 $84.39
75+ 0.985 - $6.00
100 0.991 - $0.50
36 - $430 000 $2.00
36 0.985 $400 000 $5.97
100 + 100 0.99 - $0.10
35 - $591 000 $2.00
35 0.9994 $525 000 $5.81
50 0.994 - $5.80
50 0.991 - $0.50
75 + 35 0.99 - <$0.08
75 + 35 0.99 - <$0.07
30 - $1 350 000 $1.00
30-35 0.99 - -
32 0.99 - $0.50
35 - - -
>1000 >0.99 - -
13 - $155 000 $1.00
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inclusion of resources for the cost analysis depends on the
perspective of the evaluation. We will stress this aspect
later in the discussion.
There are no accepted standards for what kind of
measures the companies need to report [13]; therefore,
it is difficult to compare the technologies from different
providers. In addition, Shendure et al. [17] state that a
simple comparison between ‘per base’ costs may be mis-
leading, because statistically more accurate bases may be
worth more than less accurate bases. Furthermore, a
direct comparison of error rates is problematic, as most
companies report errors based on sequence reads of the
particular templates that are favourable for their plat-
form. They use these particular templates for quality
control [13]. However, for health economic evaluations,
it is important to include valid error rates: these are
comparable to the sensitivity and specificity of diagnostic
instruments, which play an important role in evalua-
tions. Hence, Glenn [13] suggested that it would be
useful to develop a standard set of conditions, analyses,
and templates to compare next-generation-platforms,
chemistry, and software upgrades.
The substantial–but numerically unknown–expendi-
tures in data management and analysis, time, and
personnel, which are not yet included in the analysis,
also contribute to the ‘black box’. As Glenn [13] shows,
computational resources required to process and analyse
data vary between the platforms because short reads re-
quire analysis that is more intensive. For larger amounts
of data, it is even necessary to use high-performance
computing clusters (HPCCs). Furthermore, costs for the
instrument acquisition and maintenance need to be con-
sidered, depending on the perspective of the analysis.
According to Kircher et al. [18], these factors remain im-
portant challenges; hence, inclusion of financial invest-
ments needs to be discussed, depending on the study
perspective. Glenn’s figures [13] also assume that the
equipment will be housed in well and properly function-
ing laboratory. If genome sequencing is to be established
in a new facility, then the costs will increase consider-
ably. In this context, Tucker et al. [12] emphasise that
the initial costs, which are needed to set up a mas-
sively parallel sequencing platform, are extremely
high.
Mardis [19] highlightes challenges regarding the high
effort in analysing sequenced data. Thereby it is import-
ant to distinguish between the computational analysis in
order to identify important gen variants and the man-
ual analysis to interpret the data. Mardis emphasizes
that for the both analyses many professionals are
required, including molecular and computational biol-
ogists, geneticists, pathologists, and physicians with exten-
sive knowledge of the disease and treatment modalities.Moreover, these professionals are typically supported by
research nurses, genetic counsellors, and information
technology (IT) and systems support specialists. Further-
more, Mardis claimes that aspects of data analysis, includ-
ing the filtering of reliable variants and their clinical
validity as well as the communication of results to the
treating physician and ultimately to the patient, are under-
estimated problems and require many resources. Hence,
the costs for the sequencing process itself seem to be only
a marginal part of the whole cost of the WGS process.
This point is also emphasized by Stone and Levenson [20].
They say that genomic data have no practical use without
a complicated, costly bioinformatics analysis by specialists.
Another important factor is storage costs. The storage
of one person’s WGS data requires approximately 2.5
terabytes of disk space. Computer systems to analyse
and store data are costly [21]. Glenn [13] assumes that
the storage costs may even be higher than the analysis
costs. If the cost of the sequencing processes decreases
and the quality of sequence data and analysis improves,
re-sequencing the patient rather than re-evaluating the
old data may be more appropriate [21]. However, if
storage facilities improve in the future, the storage and
re-analysis of data might become more efficient. In many
situations, sample availability restricts or prohibits re-
sequencing. In this context, it is important to stress the
highly dynamic process of the technologies and the
difficulties in forecasting further developments. For
example, Carr et al. [22] outline the technical progress
of length and costs of base pairs over the years. Wetter-
strand [15] also documentes the development. However,
future developments are difficult to predict. Neverthe-
less, data analysis and storage should be included in a
comprehensive cost analysis.
Bick and Dimmock [21] also raise an issue regarding
the confirmation of the results. A high possibility of
false-positive results leads to insecurity and it has a
tremendous impact on health care costs. If other, more
established methods are needed to verify the results of
WGS, one must include the costs of these methods in a
health economic evaluation. For example, when analys-
ing a recessive disorder that is a compound heterozy-
gote, the two putative pathogenic variants will need to
be confirmed. Furthermore, Brick et al. state that the
cost of custom sequencing for each mutation is about
$ 200. The expectation is that, as the technology ma-
tures, the need for confirmatory testing will diminish.
However, this is not the case yet.
Other authors focus on challenges in the clinical
application of WGS and emphasize the difficulties in
integrating the patient into the information system
[19,22]. Current clinical tests, e.g. an human immuno-
deficiency virus (HIV)-test, provide patients with mean-
ingful information about a particular disorder; however,
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meaningful information yet. With respect to new-born
screening, Valle [23] is concerned whether large-scale
genomic sequencing provides any information with clin-
ical use in infants. Furthermore, patients weigh individ-
ual risks differently; they may have difficulties in
understanding and applying probabilities and risks. Fi-
nally, every person has some kind of genetic predispos-
ition to some kind of disorder; this knowledge could
result in several social problems, involving reproductive
decisions, insurance contracts, or employment, example.
g. Another issue in clinical practice will be shortcomings
of qualified manpower in the whole sequencing process.
The need for professionals with different qualifications is
discussed above. Hence, the question is who is able to
provide accurate information to patients before sequen-
cing and a skilled interpretation of the results after-
wards. It seems that there are several natural barriers to
the expansion of gene sequencing technologies into
clinical practice.
Discussion
Based on the literature findings as well as the general
knowledge on health economics e.g. [11], we developed
a list of aspects that needs to be considered before con-
ducting a health economic analysis of genome sequen-
cing. As stated in the introduction, some health
economic studies consider only cost parameters when
calculating costs of new technologies and their
economic burden. However, full economic evaluations
go beyond pure cost measurements by combining costs
and the consequences/outcomes of defined diagnostic
procedures or interventions. In the future, this list will
help researchers who plan to conduct a health economic
analysis.
Overall aim: improvement of clinical research or routine
care?
Currently, genome sequencing is mainly conducted for
clinical research proposes. However, in general, health
economic evaluations are made for clinical practice.
They are necessary to decide whether the additional
benefit of a new diagnostic technology is worth the add-
itional costs and hence eligible for reimbursement in
routine care. This separation between research and routine
care is crucial. For instance, in Germany the Statutory
Health Insurance, which decides on the reimbursement of
new diagnostic and therapeutic technologies, is not allowed
by law to support research. It is only in charge of the
health care of the insurants. Hence, if (whole) genome
sequencing for routine care was to be reimbursed, it would
be important to emphasise the direct benefit of the tech-
nology for patients and the comprehensive costs of its ap-
plication for health care systems. The following aspects allrefer to the overall aim of receiving reimbursement for
genome sequencing in clinical practice.
Technology
As the previous findings show, different technologies for
WGS (Roche/454, Helicos, etc.) vary considerably.
Hence, within the health economic evaluation it is very
important to clearly state which technology is used and
to clarify technical calibrations like coverage.
Population/indication
A famous concept, developed for epidemiologic and
clinical studies, is the so-called PICO-framework. PICO
stands for Population Indication Comparator Outcomes
and it is an important tool in evidence-based medicine.
This framework is also helpful for health economic stud-
ies. It is important to focus on a specific population with
a definite indication. In general, diagnostic or thera-
peutic technologies are not reimbursed for every kind of
population and indication. Comparable to clinical ap-
proval by the European Medicines Agency or the U.S.
Food and Drug Administration, reimbursement approval
is very restricted. This emphasises the importance of
clearly describing the populations and indications that
benefit from the new technology.
Comparator
Comparable to a classical randomized controlled study,
a new technology should always be compared to another
existing technology. This is important to identify add-
itional benefits and additional costs of the new technol-
ogy. It is advisable to take as a comparator a technology
that is already reimbursed by health insurance. Another
possibility for a comparator is ‘do nothing’, if no eligible
standard care for comparison is available. Hence, for gen-
ome sequencing, a reasonable comparator could be ‘not to
conduct a diagnostic test’.
Alternatives after sequencing
In this section, we want to emphasize the importance of
obtaining actionable results from the sequencing pro-
cess. Depending on the sequencing result, the diagnostic
procedure must result in a preventive or therapeutic
action. If, independent of the result, the output is only
‘nice to know’, then, the use of the diagnostic procedure
may not be justified. There may be an exception if a
patient has ailments for some time and their cause is
unclear. Although the diagnosis may not lead to thera-
peutic actions due to the incurable nature of the disease
(e.g. Huntington's disease), future diagnostic procedures
could be avoided and the patients would know the cause
of their indisposition. This may positively affect their
health-related quality of life.
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sequencing mainly depend on the so-called positive list
for incidental findings. This list includes all the diag-
noses that should be communicated to the physicians/
patients after sequencing. Hansson [24] recommends
investigations into whether evidence-based prevention
or treatment is available for the particular gene finding.
Otherwise, a clinical utility is questionable. Hansson also
states that DNA donors should be informed that inci-
dental findings must first be confirmed and translated
into clinical application before information is communi-
cated to them. Nevertheless, the more comprehensive
the list of communicable incidental findings is, the more
complex the health economic evaluation will be, because
various treatment options, depending on the different
diagnoses, including their effectiveness, need to be con-
sidered. However, the discussion of which criteria should
determine the indication list is continuing [25,26].Outcomes
One can distinguish between surrogate-parameters and
patient-relevant outcomes. Surrogate-parameters are mea-
sureable patient characteristics intended to substitute for a
patient-relevant clinical endpoint such as median overall-
survival. An example of a surrogate-parameter in the
context of genome sequencing is the number of detected
gene mutations. However, the role of patient-relevant out-
comes is increasing. Patient-relevant outcomes capture
those outcomes that are relevant to the patient, such as
health-related quality of life or life expectancy. In the case
of WGS, the identification of the patient-relevant outcome
is not trivial. For instance, an earlier diagnosis does not
necessarily lead to better health-related quality of life or
higher survival. Furthermore, the patient benefit that is
generated depends largely on the subsequent treatment
options. Importantly, findings that are interesting for
research purposes and that may lead to patient benefits in
the future are not to be included in such a health
economic evaluation.Probabilities
On the basis of the previous aspects, it is important to
identify reliable and valid probabilities. Based on the
sequencing data generated, how much higher is the risk
that a person will develop cancer or other diseases? How
valid and reliable is this analysis? Because sequencing
technologies also produce errors, the resulting false-
positive results and their clinical and economic impact
need to be considered in a health economic analysis. In
addition, even if a variant is accurately defined, further
evidence of both clinical validity and utility are needed if
its discovery is to be meaningful. This aspect emphasizes
the immense need for research on valid clinical data.Without these data, a full economic evaluation is not
feasible.
Costs
Finally, cost data are an obligatory part of health eco-
nomic evaluations. As discussed before, no valid cost
analysis exists so far.
A cost analysis is subdivided into the identification,
quantification, and valuation of resources. In this con-
text, it is important to stress that the number of
resource types depend on the study perspective. When
choosing the perspective of social health insurance, the
reimbursement scheme is of interest. From a mana-
gement point of view, a full cost calculation needs to
consider not only the pure sequencing costs, but also
the resources required for acquisition, maintenance, and
analysis. Because reimbursement of whole-genome
sequencing by social health insurance is not yet foreseen,
the identification and valuation of all the resource
connected to sequencing might be the first step. This
calculation could then serve as the basis for subsequent
reimbursement.
Such a calculation implies that, first, the whole
sequencing process needs to be determined and docu-
mented; hence, the resources must be quantified and
valued. Furthermore, all of the steps in the cost analysis
need to be documented separately to conduct a transparent
investigation. As the valuation mainly depends on the
respective nation, it is possible to transfer the results to
another country’s specific health care settings by simply
adjusting the valuation of the resources. In addition, the
cost model must allow different kinds of sequencing plat-
forms and sensitivity analyses. In sensitivity analyses, uncer-
tain variables are varied in order to check the robustness of
the calculation and to identify the cost-driving variables.
Hereby, it is expected that the high throughput sequencing
of gene panels will be less costly than WGS.
As all further health economic studies rely on valid
cost data, at first, a detailed cost study is needed, which
incorporates all actions connected to genome sequen-
cing–starting from informed consent and sampling to the
point of communicating the results. The results could also
serve as an input for a budget-impact analysis.
Conducting a valid cost analysis is only the first step.
Full health economic evaluations must also include the
follow-up costs as well as the benefits for patients. How-
ever, before that, considerable research is needed to
improve the clinical data, which are an important input
for health economic studies.
Because of the comprehensive and complex health
economic challenges connected to genome analyses,
health economic research will and must grow in the
future to explore the benefits and costs of these novel
technologies for patients and society.
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This review indicates that it is still a long way to
achieve the $1 000 genome–when all costs are consid-
ered, we hypothesise that this price will not be
achieved. Nevertheless, even if the $1 000 genome was
realizable one day, e.g. in the German context, it would
cost around $ 660 million to sequence every new-born
and $ 500 million to sequence every new cancer patient
[27], which would have a major public health impact.
Hence, there is further research necessary to justify
these costs in relation to the additional benefit for the
patients.
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